New Report Series from Decision Resources Combines Patient-Level Data and
Primary Research to Provide Insight into Physician Prescribing Habits
WALTHAM, Mass., Dec. 21 /PRNewswire/ -- Decision Resources, Inc., one of
the world's leading research and advisory firms focusing on pharmaceutical and
health care issues, finds that of patients who take a first-line therapy for
the treatment of schizophrenia, almost 70% will progress to a second-line
therapy within a 360-day window after diagnosis. According to the new report
entitled Treatment Algorithm Insight Series: Schizophrenia, the high rate of
progression in part signals patient and/or physician dissatisfaction with the
efficacy or tolerability of a particular drug.
"Although the market tendency is to move patients to a second-line drug
within the first year of diagnosis, when you look at it on a drug-by-drug
basis you find specific stories that differ from the average," said Alice von
Loesecke, senior director at Decision Resources. "For example, only 43% of
patients treated with Zyprexa and 46% of patients treated with Risperdal as
first-line therapies move on to second-line therapies within the first year of
diagnosis."
The new report series from Decision Resources combines in-depth primary
research with the most extensive claims-based longitudinal patient-level data
from PharMetrics(R) (http://www.pharmetrics.com) to provide exceptional
insight into physicians' actual prescribing trends and drivers of product
choice from diagnosis through multiple courses of treatment for a specific
disease. The Treatment Algorithm Insight Series examines physicians' actual
prescribing behavior as they initiate therapy and move through second- and
third-line choices.
Treatment Algorithm Insight Series: Schizophrenia
The report presents a detailed analysis of the treatment of schizophrenia
in the United States based on two sources of data -- longitudinal patient-
level claims data and primary research. The patient-level data include
treatment from initial diagnosis through three lines of therapy and analysis
of pathways to key therapies from preceding agents. Insight into the factors
driving physician prescribing behavior is drawn from an Internet survey of 78
psychiatrists (all with 20+ schizophrenia cases per month) and 75 PCPs (all
with 1+ schizophrenia cases per month).
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master their
chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources, Inc.
 back to top
Related links:
http://www.decisionresources.com
CONTACT:
Elizabeth Marshall of Decision Resources,
Inc., +1-781-296-2563, emarshall@dresources.com
|
